

thereof, a composition comprising a thrombopoietin [TPO] protein selected from the group consisting of:

(a) proteins comprising the sequence of amino acids of SEQ ID NO: 4 from amino acid residue 45 to amino acid residue 379;

(b) allelic variants of (a); and

(c) species homologs of (a) or (b), wherein said thrombopoietin protein stimulates proliferation or differentiation of myeloid or lymphoid progenitors, in combination with a pharmaceutically acceptable vehicle in an amount sufficient to produce an increase in proliferation or differentiation of erythroid cells.

6-15. (amended) The method of claim 5, wherein the thrombopoietin [TPO] comprises a sequence of amino acids selected from the group consisting of:

[the sequence of amino acids shown in SEQ ID NO: 2 from amino acid residue 1 to residue 172;

the sequence of amino acids shown in SEQ ID NO: 2 from amino acid residue 1 to residue 173;

the sequence of amino acids shown in SEQ ID NO: 2 from amino acid residue 1 to residue 175;]

the sequence of amino acids shown in SEQ ID NO: 2 from amino acid residue 1 to residue 353; and

the sequence of amino acids shown in SEQ ID NO: 2 from amino acid residue 22 to residue 353[;

the sequence of amino acids shown in SEQ ID NO: 2 from amino acid residue 22 to residue 172;

the sequence of amino acids shown in SEQ ID NO: 2 from amino acid residue 22 to residue 173;

the sequence of amino acids shown in SEQ ID NO: 2 from amino acid residue 22 to residue 175;

the sequence of amino acids shown in SEQ ID NO: 2 from amino acid residue 28 to residue 172;

the sequence of amino acids shown in SEQ ID NO: 2 from amino acid residue 28 to residue 173;

the sequence of amino acids shown in SEQ ID NO: 2 from amino acid residue 28 to residue 175; and

the sequence of amino acids shown in SEQ ID NO: 2 from amino acid residue 28 to residue 353].

Sub B² 18. (amended) A method for stimulating erythropoiesis comprising administering to a mammal in need thereof, a composition comprising a thrombopoietin [TPO] protein selected from the group consisting of:

013 (a) proteins comprising the sequence of amino acids of SEQ ID NO: 4 from amino acid residue 45 to amino acid residue 379;

(b) allelic variants of (a); and

(c) species homologs of (a) or (b), wherein said thrombopoietin protein stimulates proliferation or differentiation of myeloid or lymphoid progenitors, and erythropoietin [EPO], in combination with a pharmaceutically acceptable vehicle in an amount sufficient to produce an increase in proliferation or differentiation of erythroid cells.

15 ~~25~~. (amended) The method of claim ~~18~~¹⁹, wherein the thrombopoietin [TPO] comprises a sequence of amino acids selected from the group consisting of:

[the sequence of amino acids shown in SEQ ID NO: 2 from amino acid residue 1 to residue 172;

the sequence of amino acids shown in SEQ ID NO: 2 from amino acid residue 1 to residue 173;

the sequence of amino acids shown in SEQ ID NO: 2 from amino acid residue 1 to residue 175;]

the sequence of amino acids shown in SEQ ID NO: 2 from amino acid residue 1 to residue 353; and

the sequence of amino acids shown in SEQ ID NO: 2 from amino acid residue 22 to residue 353[;

the sequence of amino acids shown in SEQ ID NO: 2 from amino acid residue 22 to residue 172;

the sequence of amino acids shown in SEQ ID NO: 2 from amino acid residue 22 to residue 173;

the sequence of amino acids shown in SEQ ID NO: 2 from amino acid residue 22 to residue 175;

the sequence of amino acids shown in SEQ ID NO: 2 from amino acid residue 28 to residue 172;

the sequence of amino acids shown in SEQ ID NO: 2 from amino acid residue 28 to residue 173;

the sequence of amino acids shown in SEQ ID NO: 2 from amino acid residue 28 to residue 175; and

the sequence of amino acids shown in SEQ ID NO: 2 from amino acid residue 28 to residue 353].

28. (amended) A method for stimulating erythropoiesis comprising administering to a patient in need thereof, a composition comprising a thrombopoietin [TPO] protein selected from the group consisting of:

(a) proteins comprising the sequence of amino acids of SEQ ID NO: 4 from amino acid residue 45 to amino acid residue 379;

(b) allelic variants of (a); and

(c) species homologs of (a) or (b), wherein said thrombopoietin protein stimulates the proliferation or stimulation of myeloid or lymphoid progenitors, and erythropoietin [EPO], in combination with a pharmaceutically acceptable vehicle, in an amount sufficient for increasing reticulocyte counts at least 2-fold over baseline reticulocyte counts within fourteen days.

29. (amended) A method for stimulating erythropoiesis comprising administering to a patient in need thereof, a composition comprising a thrombopoietin [TPO] protein selected from the group consisting of:

(a) proteins comprising the sequence of amino acids of SEQ ID NO: 4 from amino acid residue 45 to amino acid residue 379;

*Sub
B3
cont*

(b) allelic variants of (a); and
(c) species homologs of (a) or (b), wherein said
thrombopoietin protein stimulates proliferation or
differentiation of myeloid or lymphoid progenitors, in
combination with a pharmaceutically acceptable vehicle, in
an amount sufficient for increasing reticulocyte counts at
least 2-fold over baseline reticulocyte counts within
fourteen days.

30. (amended) A method for stimulating erythropoiesis comprising administering to a patient in need thereof, a composition comprising a thrombopoietin [TPO] protein selected from the group consisting of:

(a) proteins comprising the sequence of amino acids of SEQ ID NO: 4 from amino acid residue 45 to amino acid residue 379;

(b) allelic variants of (a); and

(c) species homologs of (a) or (b), wherein said
thrombopoietin proteins stimulates proliferation or
differentiation of myeloid or lymphoid progenitors, and
erythropoietin [EPO], in combination with a
pharmaceutically acceptable vehicle, in an amount
sufficient for increasing reticulocyte counts at least 2-
fold over baseline reticulocyte counts and platelet levels
to at least 20,000/mm³ within fourteen days.

Please cancel claims 14 and 23.

REMARKS

Reconsideration of the application in view of the above amendments and following remarks is requested. Claims 9-13, 15-22, and 24-30 are now in the case. Claims 9, 15, 18, 25, 28, 29, and 30 have been amended. Claims 1-8, 14 and 23 have been canceled.

The Examiner has objected to the specification and requested a statement under 37 C.F.R. §1.821(f),